Latest News and Press Releases

-- Company delivers on mission to transform women’s health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full...

-- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc® -- ATLANTA, March 18, 2025 (GLOBE NEWSWIRE)...

ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of...

--Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners-- ATLANTA, Feb. 25, 2025 ...

ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of...

ATLANTA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of...

New York, NY, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Bonafide Health, LLC, a women’s healthcare company committed to providing effective and clinically studied solutions for common perimenopause and...

New York, NY, July 08, 2024 (GLOBE NEWSWIRE) -- Bonafide Health, LLC, a women’s healthcare company that provides hormone-free, clinically researched solutions to effectively relieve perimenopause...

ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) --         Bonafide® Health, LLC, a women’s healthcare company offering naturally powerful solutions to manage common perimenopause and menopause symptoms,...